NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia
· Delayed Price · Currency is AUD 0.105
+0.005 (5.00%)
Mar 10, 2026, 9:59 AM AEST
ASX:NSB Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Other Revenue | 0.32 | - | 2.21 | 4.95 | - | 0.96 | Upgrade
|
| Revenue | 0.32 | - | 2.21 | 4.95 | - | 0.96 | Upgrade
|
| Revenue Growth (YoY) | -85.63% | - | -55.34% | - | - | - | Upgrade
|
| Cost of Revenue | 0.05 | -0 | 0.02 | 0.05 | 0.07 | 0.04 | Upgrade
|
| Gross Profit | 0.27 | 0 | 2.19 | 4.91 | -0.07 | 0.92 | Upgrade
|
| Selling, General & Admin | 1.42 | 0.99 | 1.36 | 1.75 | 1.8 | 1.28 | Upgrade
|
| Research & Development | 0.55 | 0.13 | 0.49 | 4.03 | 7.22 | 2.22 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.67 | 0.09 | 0.09 | 0.05 | 0.05 | 0.05 | Upgrade
|
| Operating Expenses | 3.64 | 2.01 | 2.03 | 6.08 | 10.44 | 4.18 | Upgrade
|
| Operating Income | -3.37 | -2.01 | 0.16 | -1.17 | -10.5 | -3.26 | Upgrade
|
| Interest Expense | -0 | -0 | -0.01 | -0 | - | -0 | Upgrade
|
| Interest & Investment Income | 0.19 | 0.17 | 0.18 | 0.11 | 0.07 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -3.18 | -1.85 | 0.32 | -1.07 | -10.44 | -3.24 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.06 | Upgrade
|
| Pretax Income | -3.18 | -1.85 | 0.32 | -1.07 | -10.44 | -3.18 | Upgrade
|
| Net Income | -3.18 | -1.85 | 0.32 | -1.07 | -10.44 | -3.18 | Upgrade
|
| Net Income to Common | -3.18 | -1.85 | 0.32 | -1.07 | -10.44 | -3.18 | Upgrade
|
| Shares Outstanding (Basic) | 240 | 147 | 145 | 143 | 143 | 143 | Upgrade
|
| Shares Outstanding (Diluted) | 240 | 147 | 145 | 143 | 143 | 143 | Upgrade
|
| Shares Change (YoY) | 64.61% | 1.49% | 0.72% | - | - | 83.04% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | 0.00 | -0.01 | -0.07 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | 0.00 | -0.01 | -0.07 | -0.02 | Upgrade
|
| Free Cash Flow | -1.39 | -0.94 | 0.04 | -2.3 | -6.95 | -2.63 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | - | -0.02 | -0.05 | -0.02 | Upgrade
|
| Gross Margin | 85.34% | - | 98.90% | 99.07% | - | 95.87% | Upgrade
|
| Operating Margin | -1058.85% | - | 7.02% | -23.65% | - | -340.53% | Upgrade
|
| Profit Margin | -999.47% | - | 14.66% | -21.57% | - | -331.45% | Upgrade
|
| Free Cash Flow Margin | -436.90% | - | 1.92% | -46.52% | - | -274.46% | Upgrade
|
| EBITDA | -2.7 | -1.92 | 0.25 | -1.11 | -10.44 | -3.2 | Upgrade
|
| EBITDA Margin | - | - | 11.15% | -22.48% | - | - | Upgrade
|
| D&A For EBITDA | 0.67 | 0.09 | 0.09 | 0.06 | 0.06 | 0.06 | Upgrade
|
| EBIT | -3.37 | -2.01 | 0.16 | -1.17 | -10.5 | -3.26 | Upgrade
|
| EBIT Margin | - | - | 7.02% | -23.65% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.